Cabana Michael D, Marsh Anne, Treadwell Marsha J, Stemmler Peggy, Rowland Michael, Bender M A, Bhasin Neha, Chung Jong H, Hassell Kathryn, Abdul Rashid N F Nik, Wong Trisha E, Bardach Naomi S
Department of Pediatrics, University of California, San Francisco (UCSF), San Francisco, Calif.
Epidemiology & Biostatistics, University of California, San Francisco (UCSF), San Francisco, Calif.
Pediatr Qual Saf. 2020 Dec 28;6(1):e379. doi: 10.1097/pq9.0000000000000379. eCollection 2021 Jan-Feb.
Sickle cell disease is a complex chronic disorder associated with increased morbidity and early mortality. The Pediatric Quality Measures Program has developed new sickle cell-specific quality measures focused on hydroxyurea (HU) counseling and annual transcranial Doppler (TCD) screening; however, these measures have not been used in a clinical setting to inform quality improvement (QI) efforts.
From 2017 to 2018, 9 sickle cell subspecialty clinics from the Pacific Sickle Cell Regional Collaborative conducted a year-long QI collaborative focused on improving the percentage of patients with HU counseling and TCD screening based on the new quality measures. After an initial kick-off meeting, the 9 sites participated in monthly conference calls. We used run charts annotated with plan-do-study-act cycle activities to track each site's monthly progress and the overall mean percentage for the entire collaborative.
There was an overall improvement in the aggregate HU counseling from 85% to 98% ( < 0.01). For TCD screening, referral frequency changed from 85% to 90% ( = 0.76). For both measures, the variation in frequencies decreased over the year.
Over 1 year, we found that a regional QI collaborative increased HU counseling. Although referral for TCD screening increased, there was no overall change in TCD completion. Overall, this QI report's findings can help clinicians adopt and implement these quality measures to improve outcomes in children.
镰状细胞病是一种复杂的慢性疾病,与发病率增加和早期死亡率相关。儿科质量测量项目制定了新的镰状细胞病特异性质量测量指标,重点关注羟基脲(HU)咨询和年度经颅多普勒(TCD)筛查;然而,这些指标尚未在临床环境中用于指导质量改进(QI)工作。
2017年至2018年,太平洋镰状细胞病区域协作组的9家镰状细胞病专科诊所开展了为期一年的QI协作,重点是根据新的质量指标提高接受HU咨询和TCD筛查的患者比例。在首次启动会议后,9个地点参加了月度电话会议。我们使用标注有计划-执行-研究-行动循环活动的运行图来跟踪每个地点的月度进展以及整个协作组的总体平均百分比。
HU咨询的总体情况从85%提高到98%(<0.01)。对于TCD筛查,转诊频率从85%变为90%(P = 0.76)。对于这两项指标,频率的变化在这一年中有所下降。
在1年多的时间里,我们发现区域QI协作提高了HU咨询。虽然TCD筛查的转诊增加了,但TCD完成情况总体没有变化。总体而言,这份QI报告的结果可以帮助临床医生采用和实施这些质量指标,以改善儿童的治疗效果。